KSQ Therapeutics Stock

ksqtx.comBioTechFounded: 2015Funding to Date: $157.46MM

KSQ Therapeutics is the developer of a genome-scale precision functional genomics platform, called CRISPRomics, designed to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for KSQ Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

David Meeker MD
Chief Executive Officer & Board Member
John Trzupek Ph.D
Interim Chief Financial Officer & Head, Corporate Development
Frank Stegmeier Ph.D
Chief Scientific Officer
David Sabatini Ph.D
Co-Founder
Tim Wang Ph.D
Co-Founder
William Hahn MD
Co-Founder
Jonathan Weissman Ph.D
Co-Founder

Board Members

Alan Crane
Polaris Partners
David Berry Ph.D
Flagship Pioneering
David Meeker MD
George Golumbeski Ph.D
James Gilbert
Flagship Pioneering
Pearl Huang Ph.D
Richard Moscicki MD
Theo Melas-Kyriazi

Other companies like KSQ Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of